MD HB340 | 2024 | Regular Session

Status

Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on January 17 2024 - 25% progression
Action: 2024-01-26 - Hearing 2/08 at 1:00 p.m.
Pending: House Health and Government Operations Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Requiring the Governor in fiscal year 2025 and each fiscal year thereafter to include in the annual budget bill an appropriation of at least $1,000,000 for the Prescription Drug Affordability Fund which provides funding for the Board; and requiring the Board, under certain circumstances, to establish a process for setting upper payment limits for all purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to affordability challenges.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Prescription Drug Affordability Board - Authority for Upper Payment Limits and Funding (The Lowering Prescription Drug Costs For All Marylanders Now Act)

Sponsors


History

DateChamberAction
2024-01-26HouseHearing 2/08 at 1:00 p.m.
2024-01-17HouseFirst Reading Health and Government Operations

Same As/Similar To

SB388 (Crossfiled) 2024-01-24 - Hearing 2/07 at 2:00 p.m. (Finance)

Subjects


Code Citations

ChapterArticleSectionCitation TypeStatute Text
Health - General212C-11(n/a)See Bill Text
Health - General212C-13(n/a)See Bill Text
Health - General212C-14(n/a)See Bill Text
Health - General212C-16(n/a)See Bill Text

Maryland State Sources


Bill Comments

feedback